Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | IDO1 | P14902 | 3/20 | 0.61 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | GAA | P10253 | 6/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | TEK | Q02763 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21064028 | 0.79 | IDO1 (0.72) | HSD17B10IDO1NTRK1MAPTGAA | |
| SCHEMBL4716238 | 0.78 | MAPK1 (0.49) | HSD17B10MAPTGAATP53 | |
| SCHEMBL24620602 | 0.77 | IDO1 (0.65) | HSD17B10IDO1NTRK1MAPTGAA | |
| SCHEMBL6644562 | 0.75 | ALDH1A1 (0.67) | HSD17B10NTRK1MAPTGAAPTGS2 | |
| SCHEMBL22761661 | 0.75 | HSD17B10 (0.59) | HSD17B10IDO1NTRK1MAPTGAA | |
| SCHEMBL4720268 | 0.73 | TSHR (0.43) | HSD17B10IDO1NTRK1TP53POLB | |
| SCHEMBL22648873 | 0.73 | DYRK1A (0.56) | HSD17B10IDO1NTRK1MAPTGAA | |
| Hydrochloric Acid SCHEMBL18128822 | 0.73 | IDO1 (0.56) | HSD17B10IDO1NTRK1MAPTGAA | |
| SCHEMBL7851176 | 0.72 | PTGS2 (0.76) | HSD17B10IDO1NTRK1MAPTGAA | |
| SCHEMBL4715464 | 0.72 | ALOX5 (0.69) | HSD17B10IDO1NTRK1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1218383-B1 | BICYCLIC IMIDAZO-5-YL-AMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2008-11-05 | — | — | EP | claimed |
| US-20040023927-A1 | Bicyclic imidazo-5-yl-amine derivatives | GRUENENTHAL GMBH (DE) | 2004-02-05 | — | — | US | claimed |
| US-6657064-B2 | For use as analgesics | GRUENENTHAL GMBH (DE) | 2003-12-02 | — | — | US | claimed |
| US-20020183320-A1 | Bicyclic imidazo-5-yl-amine derivatives | GRUENENTHAL GMBH (DE) | 2002-12-05 | — | — | US | claimed |
| US-6936631-B2 | Bicyclic imidazo-5-yl-amine derivatives | GRUENENTHAL GMBH (DE) | 2005-08-30 | — | — | US | disclosed |
| US-20040023927-A1 | Bicyclic imidazo-5-yl-amine derivatives | GRUENENTHAL GMBH (DE) | 2004-02-05 | — | — | US | disclosed |
| US-6657064-B2 | For use as analgesics | GRUENENTHAL GMBH (DE) | 2003-12-02 | — | — | US | disclosed |
| US-20020183320-A1 | Bicyclic imidazo-5-yl-amine derivatives | GRUENENTHAL GMBH (DE) | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183320-A1 | Bicyclic imidazo-5-yl-amine derivatives | ACHE, P2RX5, CNR1 | HSD17B10 4012/4885IDO1 631/4885NTRK1 2468/4885 |
| US-20040023927-A1 | Bicyclic imidazo-5-yl-amine derivatives | ACHE, P2RX5, CNR1 | HSD17B10 4012/4885IDO1 631/4885NTRK1 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.